{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:46:35Z","timestamp":1787859995475,"version":"build-2784847793"},"reference-count":40,"publisher":"Massachusetts Medical Society","issue":"23","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100022850","name":"Myovant Sciences, GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100022850","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2020,6,4]]},"DOI":"10.1056\/nejmoa2004325","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T08:07:35Z","timestamp":1590739655000},"page":"2187-2196","source":"Crossref","is-referenced-by-count":406,"title":["Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer"],"prefix":"10.1056","volume":"382","author":[{"given":"Neal D.","family":"Shore","sequence":"first","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Cookson","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Saltzstein","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Tutrone","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Akaza","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bossi","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"van Veenhuyzen","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Selby","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Fan","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Kang","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Walling","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[{"name":"From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network,..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.08.008"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.45.1.391"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02393-2"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.2.238"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.002"},{"key":"e_1_3_5_7_2","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Prostate cancer 2019 version 4.2019. August 19 2019 (https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/prostate-patient.pdf)."},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61831-7"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2018.1522372"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2442"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08183.x"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2012.02997.x"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2770"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2020.03.001","article-title":"The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant\/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomized, open-label, parallel-group phase 2 trial.","author":"Dearnaley DP","year":"2020","unstructured":"Dearnaley DP, Saltzstein DR, Sylvester JE, et al. The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant\/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomized, open-label, parallel-group phase 2 trial. Eur Urol 2020 April 6 (Epub ahead of print).32273183","journal-title":"Eur Urol"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.34.2_suppl.200"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"e_1_3_5_17_2","unstructured":"Food and Drug Administration. Non-inferiority clinical trials to establish effectiveness: guidance for industry. November 2016 (https:\/\/www.fda.gov\/media\/78504\/download)."},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3461"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.173.4001.1036"},{"key":"e_1_3_5_20_2","first-page":"626","article-title":"The role of LHRH antagonists in the treatment of prostate cancer.","volume":"23","author":"Crawford ED","year":"2009","unstructured":"Crawford ED, Hou AH. The role of LHRH antagonists in the treatment of prostate cancer. Oncology (Williston Park) 2009;23:626-630.19626830","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.04.016"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2017.06.008"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2826.2009.01842.x"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm200216q"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.12.001"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2018.01.06"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00309-X"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201546"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.15382.1"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.10.032"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000384"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep26220"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.06.018"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.06.036"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz766"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/820403"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.09.001"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp404"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000714"},{"key":"e_1_3_5_40_2","first-page":"296","article-title":"Medication adherence, treatment patterns, and dose reduction in patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate or enzalutamide.","volume":"10","author":"Behl AS","year":"2017","unstructured":"Behl AS, Ellis LA, Pilon D, Xiao Y, Lefebvre P. Medication adherence, treatment patterns, and dose reduction in patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate or enzalutamide. Am Health Drug Benefits 2017;10:296-303.28975013","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_5_41_2","first-page":"477","article-title":"Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer.","volume":"20","author":"Lafeuille M-H","year":"2014","unstructured":"Lafeuille M-H, Grittner AM, Lefebvre P, et al. Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer. J Manag Care Spec Pharm 2014;20:477-484.24761819","journal-title":"J Manag Care Spec Pharm"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2004325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:46:36Z","timestamp":1711485996000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2004325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":40,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020,6,4]]}},"alternative-id":["10.1056\/NEJMoa2004325"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2004325","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738043806.793582529","asserted-by":"object"}]},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,4]]}}}